Submission of the Financial Results for the year ended March 31, 2026

Profit growth above 25%EBITDA margin expansionExceptional itemGoing-concern doubtResults View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.3%Reaction day

₹1549.50

prior close

₹1520.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.1%-5.4% vs market

Pharmaceuticals peers, median of 164sector-0.1%-5.2% vs sector

On the reaction day the stock moved 5.4 pts less than Nifty Midcap 150 and 5.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

-2.0

15m

-2.6

30m

-2.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.3+0.1-5.4-0.1-5.2

Next day

-6.1+1.0-7.1+0.9-7.0

-5.9+1.4-7.3+0.9-6.8

-7.6+1.8-9.4+0.7-8.3

-8.2+0.4-8.6+0.9-9.1

-7.3-1.0-6.3+0.0-7.3

-7.4-1.2-6.2-0.0-7.4

15d

-9.4+0.5-9.9+1.2-10.6

-3.5+2.6-6.1+3.0-6.5

-1.1+2.0-3.1+4.7-5.9

+3.9+4.2-0.3+7.9-4.1

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma reported strong full-year FY2026 results with standalone revenue of ₹1,10,554 million, up ~2.5% YoY, while standalone profit after tax surged 38% to ₹24,148 million from ₹17,468 million in FY2025. Standalone EPS rose to ₹41.58 from ₹29.97. On a consolidated basis, revenue grew 6.4% to ₹3,33,847 million and consolidated PAT increased 0.6% to ₹35,030 million. The company completed an ₹8,000 million share buyback in May 2026 and announced acquisition of Lannett Company LLC (US) subject to regulatory approvals. Exceptional items of ₹173.8 million (standalone) and ₹653.3 million (consolidated) were recorded due to new Indian Labour Codes impacting employee benefit liabilities.

Likely market impact

The 38% standalone PAT growth and EPS beat indicate strong operational performance, though modest revenue growth may temper enthusiasm. The completed buyback will support EPS going forward. Shareholders should note ongoing expansion investments and acquisitions that may drive future revenue growth.